Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles

References

• LiMZhangWWangBGaoYSongZZhengQCLigand-based targeted therapy: a novel strategy for hepatocellular carcinomaInt J Nanomedicine2016115645566927920520
   PubMed Web of Science ®Google Scholar
• ChackoSSamantaSHepatocellular carcinoma: A life-threatening diseaseBiomed Pharmacother2016841679168827823920
   PubMed Web of Science ®Google Scholar
• ReyaTMorrisonSJClarkeMFWeissmanILStem cells, cancer, and cancer stem cellsNature2001414685910511111689955
   PubMed Web of Science ®Google Scholar
• ShenSXiaJXWangJNanomedicine-mediated cancer stem cell therapyBiomaterials20167411826433488
   PubMed Web of Science ®Google Scholar
• KassemNMReview article: cancer stem cells: from identification to eradicationJ Egypt Natl Canc Inst200820320921520424650
   PubMedGoogle Scholar
• YamashitaTWangXWCancer stem cells in the development of liver cancerJ Clin Invest201312351911191823635789
   PubMed Web of Science ®Google Scholar
• WuYWuPYCD133 as a marker for cancer stem cells: progresses and concernsStem Cells Dev20091881127113419409053
   PubMed Web of Science ®Google Scholar
• TirinoVDesiderioVPainoFCancer stem cells in solid tumors: an overview and new approaches for their isolation and characterizationFaseb J2013271132423024375
   PubMed Web of Science ®Google Scholar
• WangMXieFWenXTherapeutic PEG-ceramide nanomicelles synergize with salinomycin to target both liver cancer cells and cancer stem cellsNanomedicine20171291025104228440698
   PubMed Web of Science ®Google Scholar
• GongZChenDXieFCodelivery of salinomycin and doxorubicin using nanoliposomes for targeting both liver cancer cells and cancer stem cellsNanomedicine201611192565257927647449
   PubMed Web of Science ®Google Scholar
• XieFZhangSLiuJCodelivery of salinomycin and chloroquine by liposomes enables synergistic antitumor activity in vitroNanomedicine201611141831184627391366
   PubMed Web of Science ®Google Scholar
• MaoXLiuJGongZiRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cellsNanomedicine201510172677269526355733
   PubMed Web of Science ®Google Scholar
• ChafferCLBrueckmannIScheelCNormal and neoplastic nonstem cells can spontaneously convert to a stem-like stateProc Natl Acad Sci U S A2011108197950795521498687
   PubMed Web of Science ®Google Scholar
• IliopoulosDHirschHAWangGStruhlKInducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretionProc Natl Acad Sci U S A201110841397140221220315
   PubMed Web of Science ®Google Scholar
• GuptaPBFillmoreCMJiangGStochastic state transitions give rise to phenotypic equilibrium in populations of cancer cellsCell2011146463364421854987
   PubMed Web of Science ®Google Scholar
• GaoJLiWGuoYFengSSNanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cellsNanomedicine201611243261328227854161
   PubMed Web of Science ®Google Scholar
• VasiliouVVasiliouKNebertDWHuman ATP-binding cassette (ABC) transporter familyHum Genomics20093328129019403462
   PubMedGoogle Scholar
• GlavinasHKrajcsiPCserepesJSarkadiBThe role of ABC transporters in drug resistance, metabolism and toxicityCurr Drug Deliv200411274216305368
   PubMedGoogle Scholar
• DeanMFojoTBatesSTumour stem cells and drug resistanceNat Rev Cancer20055427528415803154
   PubMed Web of Science ®Google Scholar
• GuptaPBOnderTTJiangGIdentification of selective inhibitors of cancer stem cells by high-throughput screeningCell2009138464565919682730
   PubMed Web of Science ®Google Scholar
• CojocMMäbertKMudersMHDubrovskaAA role for cancer stem cells in therapy resistance: cellular and molecular mechanismsSemin Cancer Biol201531162724956577
   PubMed Web of Science ®Google Scholar
• SukowatiCHRossoNCrocèLSTiribelliCHepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinomaWorld J Hepatol20102311412621160982
   PubMedGoogle Scholar
• AlisiAChoWCLocatelliFFruciDMultidrug resistance and cancer stem cells in neuroblastoma and hepatoblastomaInt J Mol Sci20131412247062472524351843
   PubMed Web of Science ®Google Scholar
• WuCPCalcagnoAMAmbudkarSVReversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategiesCurr Mol Pharmacol2008129310519079736
   PubMedGoogle Scholar
• GlavinasHKrajcsiPCserepesJSarkadiBThe role of ABC transporters in drug resistance, metabolism and toxicityCurr Drug Deliv200411274216305368
   PubMedGoogle Scholar
• SparreboomAPlantingASJewellRCClinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoproteinAnticancer Drugs199910871972810573204
   PubMed Web of Science ®Google Scholar
• HubensackMMüllerCHöcherlPEffect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude miceJ Cancer Res Clin Oncol2008134559760717932689
   PubMed Web of Science ®Google Scholar
• KarlaPKEarlaRBodduSHJohnstonTPPalDMitraAMolecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cellsCurr Eye Res20093411919172464
   PubMed Web of Science ®Google Scholar
• Nieto MontesinosRBéduneauALamprechtAPellequerYLiposomes Coloaded with Elacridar and Tariquidar To Modulate the P-Glycoprotein at the Blood-Brain BarrierMol Pharm201512113829383826390138
   PubMedGoogle Scholar
• WongHLBendayanRRauthAMWuXYSimultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancerJ Control Release2006116327528417097178
   PubMed Web of Science ®Google Scholar
• SinghMSLamprechtACargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicinInt J Pharm2015478274575225437111
   PubMedGoogle Scholar
• PlantingASSonneveldPvan der GaastAA phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumorsCancer Chemother Pharmacol2005551919915565444
   PubMed Web of Science ®Google Scholar
• ZhaoYAlakhovaDYKabanovAVCan nanomedicines kill cancer stem cells?Adv Drug Deliv Rev20136513–141763178324120657
   PubMed Web of Science ®Google Scholar
• ChenDXieFSunDYinCGaoJZhongYNanomedicine-Mediated Combination Drug Therapy in TumorOpen Pharmaceutical Sciences Journal201741110
   Google Scholar
• XieFYXuWHYinCZhangGQZhongYQGaoJNanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive systemWorld J Gastrointest Oncol201681073574427795813
   PubMed Web of Science ®Google Scholar
• GaoJFengSSGuoYNanomedicine for treatment of cancer stem cellsNanomedicine20149218118424552558
   PubMed Web of Science ®Google Scholar
• GaoJFengSSGuoYNanomedicine against multidrug resistance in cancer treatmentNanomedicine20127446546822471716
   PubMed Web of Science ®Google Scholar
• BregoliLMoviaDGavigan-ImedioJDLysaghtJReynoldsJPrina-MelloANanomedicine applied to translational oncology: A future perspective on cancer treatmentNanomedicine20161218110326370707
   PubMed Web of Science ®Google Scholar
• ZhaoZLouSHuYZhuJZhangCA Nano-in-Nano Polymer-Dendrimer Nanoparticle-Based Nanosystem for Controlled Multidrug DeliveryMol Pharm20171482697271028704056
   PubMed Web of Science ®Google Scholar
• VogusDREvansMAPusuluriAA hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancerJ Control Release201726719120228823957
   PubMed Web of Science ®Google Scholar
• GaoJKouGChenHTreatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab’) fragmentsMol Cancer Ther20087103399340718852143
   PubMed Web of Science ®Google Scholar
• ChenHGaoJLuYPreparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapyJ Control Release2008128320921618450313
   PubMed Web of Science ®Google Scholar
• GuoYLuoJTanSOtienoBOZhangZThe applications of Vitamin E TPGS in drug deliveryEur J Pharm Sci201349217518623485439
   PubMed Web of Science ®Google Scholar
• ZhouJZhaoWYMaXThe anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancerBiomaterials201334143626363823422592
   PubMed Web of Science ®Google Scholar
• YaoHJJuRJWangXXThe antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral deliveryBiomaterials201132123285330221306774
   PubMed Web of Science ®Google Scholar
• WangATLiangDSLiuYJQiXRRoles of ligand and TPGS of micelles in regulating internalization, penetration and accumulation against sensitive or resistant tumor and therapy for multidrug resistant tumorsBiomaterials20155316017225890716
   PubMed Web of Science ®Google Scholar
• GhoshSKarNBeraTOleanolic acid loaded poly lactic co-glycolic acid-vitamin E TPGS nanoparticles for the treatment of Leishmania donovani infected visceral leishmaniasisInt J Biol Macromol201693Pt A96197027645930
   PubMedGoogle Scholar
• WangYYZhangDDKongYYCS/PAA@TPGS/PLGA nanoparticles with intracellular pH-sensitive sequential release for delivering drug to the nucleus of MDR cellsColloids Surf B Biointerfaces201614571672727289313
   PubMed Web of Science ®Google Scholar
• ZhuXZengXZhangXThe effects of quercetin-loaded PLGA-TPGS nanoparticles on ultraviolet B-induced skin damages in vivoNanomedicine201612362363226656634
   PubMed Web of Science ®Google Scholar
• ChouTCTalalyPA simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systemsJ Biol Chem19772521864386442893418
   PubMed Web of Science ®Google Scholar
• ZhuHChenHZengXCo-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistanceBiomaterials20143572391240024360574
   PubMed Web of Science ®Google Scholar
• SuXSongHNiuFCo-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multi-drug resistanceNanomedicine201510132033205026084553
   PubMed Web of Science ®Google Scholar
• BarenholzYDoxil® – the first FDA-approved nano-drug: lessons learnedJ Control Release2012160211713422484195
   PubMed Web of Science ®Google Scholar
• WibroePPAhmadvandDOghabianMAYaghmurAMoghimiSMMoeinmoghimiSAn integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosomeJ Control Release20162211826608877
   PubMed Web of Science ®Google Scholar
• LeonardRCWilliamsSTulpuleALevineAMOliverosSImproving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet)Breast200918421822419656681
   PubMed Web of Science ®Google Scholar
• YoukHJLeeEChoiMKEnhanced anticancer efficacy of alpha-tocopheryl succinate by conjugation with polyethylene glycolJ Control Release20051071435216081183
   PubMed Web of Science ®Google Scholar
• ConstantinouCPapasAConstantinouAIVitamin E and cancer: An insight into the anticancer activities of vitamin E isomers and analogsInt J Cancer2008123473975218512238
   PubMed Web of Science ®Google Scholar